We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual functio... Clearside Biomedical Inc is a United States-based clinical biopharmaceutical company. It is engaged in developing pharmacological therapies to treat blinding disease of the eye. The product candidates of the company focus on a disease affecting the retina and aim to restore or improve visual function primarily by reducing the macular edema associated with several diseases affecting vision. Show more
ALPHARETTA, Ga., March 18, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye...
- Phase 2b ODYSSEY Wet AMD Trial Remains on Track with Topline Data Expected in Q3 2024 - - Partner Programs Continue to Report Positive Clinical Data Utilizing SCS Microinjector®...
ALPHARETTA, Ga., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through...
false 0001539029 0001539029 2024-02-06 2024-02-06 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT...
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271902 PROSPECTUS SUPPLEMENT (To Prospectus Dated May 19, 2023) 11,111,111 Shares of Common Stock...
ALPHARETTA, Ga., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (“Clearside” or the “Company”) (NASDAQ: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies...
0001539029false00015390292024-01-312024-01-31 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIPFiled pursuant to Section 16(a) of the Securities Exchange...
="/Images/box-checked.jpg" alt="Checkbox checked">144: Remarks and SignatureRemarksDate of Notice01/19/2024ATTENTION: The person for whose account the securities to which this notice relates are...
0001539029false00015390292023-12-222023-12-22 UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1199 | -7.01169590643 | 1.71 | 1.8 | 1.5 | 344005 | 1.72756136 | CS |
4 | 0.1601 | 11.1958041958 | 1.43 | 2.12 | 1.33 | 702111 | 1.67442387 | CS |
12 | 0.1001 | 6.71812080537 | 1.49 | 2.12 | 1.1 | 352509 | 1.5710611 | CS |
26 | 0.7599 | 91.5321609251 | 0.8302 | 2.12 | 0.650101 | 254752 | 1.36966158 | CS |
52 | 0.6527 | 69.6287604011 | 0.9374 | 2.12 | 0.650101 | 195313 | 1.28712504 | CS |
156 | -0.6699 | -29.6415929204 | 2.26 | 7.73 | 0.650101 | 557805 | 3.4380733 | CS |
260 | 0.2201 | 16.0656934307 | 1.37 | 7.73 | 0.56 | 589380 | 2.82486064 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions